I always thought IONIC would be a hard sell to recruit for compared to DARRT or CEP which are mostly addition to standard of care treatments.
It would take a brave soul to commit to trialling a combination which is trying to work in a place where opdivo alone wouldn't or hasn't. The fact the trial continues does offer hope that some responses have been tallied.
Our new CEO does seem determined to commit to a new CR from the lowest possible price point, either that or she knows more than we do?
I always thought IONIC would be a hard sell to recruit for...
Add NOX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
11.0¢ |
Change
0.005(4.76%) |
Mkt cap ! $32.14M | |||
| Open | High | Low | Value | Volume |
| 11.5¢ | 11.5¢ | 11.0¢ | $18.94K | 171.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 50000 | 11.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 12.5¢ | 66800 | 1 |
View Market Depth
| Last trade - 14.48pm 08/11/2024 (20 minute delay) ? |
| NOX (ASX) Chart |